CN103893194A - Traditional Chinese medicine preparation and production method thereof - Google Patents
Traditional Chinese medicine preparation and production method thereof Download PDFInfo
- Publication number
- CN103893194A CN103893194A CN201410166661.1A CN201410166661A CN103893194A CN 103893194 A CN103893194 A CN 103893194A CN 201410166661 A CN201410166661 A CN 201410166661A CN 103893194 A CN103893194 A CN 103893194A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- chimonin
- mogroside
- traditional chinese
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a traditional Chinese medicine preparation which has the effect of clearing heat from throat and a production method thereof. The active ingredients of the traditional Chinese medicine preparation are a mango leaf extract (mangiferin) and a fructus momordicae extract (mogroside). By adopting an idiomatical method of the traditional Chinese medicine preparations, oral solid traditional Chinese medicine preparations such as troches, granules, capsules and buccal tablets and oral liquid traditional Chinese medicine preparations such as mixtures, syrups and soft extracts are developed. Results of animal pharmacology and toxicity tests show that the traditional Chinese medicine preparation is remarkable in curative effect and free of adverse reactions.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation with moistening and cleaning throat effect, particularly Chinese medicine preparation and the production method thereof of exploitation take chimonin and mogroside as active component.
Background technology
Fructus Mangifera Indicae is Anacardiaceae plant Mangifera indica L..As a kind of industrial crops, the mango cultivated area in recent Guangxi increases gradually, therefore also increases severely as the Folium mangiferae quantity of agricultural wastes thereupon.The processing of Folium mangiferae be generally to direct burning in the past or rotted in orchard, having caused the great wasting of resources.
Folium mangiferae is the Chinese crude drug that has very much medical value, according to the literature, Folium mangiferae acid, sweet, taste is cool or flat, have that antiasthmatic-antitussive eliminates the phlegm, circulation of qi promoting dredge stagnant, go that acute diseases such as cholera and sunstroke is long-pending, immunity, antiinflammatory, analgesia, hepatic cholagogic, anti peroxidation of lipid, antiviral, antitumor, the effect such as antibacterial, the disease such as be mainly used in treating heat stagnation stomachache, flatulence, infantile malnutrition, quench one's thirst." Fujian Chinese medicine " 2001,32 (2) publications " thin layer chromatography of compound recipe Folium mangiferae and antibacterial tests " are mentioned, mango leaf extract is carried out to in-vitro antibacterial experiment, result shows, Folium mangiferae all has stronger antibacterial action to golden Portugal 25023 bacterium, the resistance to bacterium in capital, golden Portugal, white Pu coccus, Nai Shi coccus, bacillus pyocyaneus, escherichia coli, Fu Shi bacillus, Bacillus typhi.Some medical mechanisms of chimonin delivered " chimonin pharmacology activity research progress " and summarized by " Chinese patent medicine " 2011,33 (5).1. antiinflammatory action.Find by ultraviolet spectrophotometry and radioimmunology research, the chimonin of various dose all can reduce the level of PGE2 (PGE2) in mouse back air bag inflammatory exudate and systemic inflammatorome rabbit hypothalamus; By (SRS-A) level of slow reacting substance in guinea pig tissues and guinea pig ileum shrinkage amplitude are measured, also find that chimonin can suppress the release that guinea pig ileum is shunk, reduced lung tissue SRS-A, illustrates that chimonin has obvious antiinflammatory action.In addition, chimonin can also suppress the inflammatory reaction of mast cell mediated, and the struvite ear edema of the mice of arachidonic acid-induction is had to good therapeutic effect, can also control arachidonic amount in macrophage simultaneously.2. antioxidation, in Mice Body, inject left-handed glucosides ferrum, cause the damage of mice iron overload, then inject chimonin, find after deliberation no matter be that chimonin can stop iron overload in blood plasma or in liver, and can reduce lipid peroxidation enzyme in blood plasma and liver and the activity of glutathion peroxidase, thereby increase the glutathione content in blood plasma and liver, strengthen the adhesion of the interior superoxide dismutase of blood plasma and ferrum, aspartate transaminase and alanine aminotransferase in liver are reduced, and make general Fil, a large amount of abnormal storehouse (Kupffer) cell also have obvious minimizing, show the antioxidation of chimonin.In addition,, with urine streptomycin induction heart and the damage of renal tissue oxidized form, result has confirmed that chimonin has repair to heart and the renal tissue of damage.In to the research of suffering from albinism mice, further prove that chimonin has the oxygen-derived free radicals of removing and good antioxidation.3. antivirus action.Duck is carried out after intravenous injection DHB, continuous oral chimonin 10d, the laggard promoting the circulation of blood sorting of drug withdrawal 3d from, adopt spot hybridization and autoradiographic technique to observe the dynamic change of serum hbv dna, during result shows administration, chimonin has obvious inhibitory action to hepatitis B virus DNA.In addition, chimonin can obviously suppress the increment of HSV-II, and this inhibitory action is to realize by suppressing the synthetic of its DNA.4. the therapeutical effect of pair diabetes.In the trouble diabetic mice body of Streptozocin induction, verify in chimonin treatment hyperglycemia and the experiment of atherosclerosis effect and also find, chimonin can obviously reduce the blood sugar level of mice, and the level that can reduce T-CHOL in blood plasma, demonstrates good antihyperlipidemic and antiatherogenic therapeutic effect; In normal mouse body, injection chimonin has improved the tolerance degree of mice oral disposition glucose.While diabetes rat being carried out to pharmacodynamic action research with chimonin, find, chimonin may increase by suppressing glyconeogenesis the secretion of insulin, brings into play the effect of its treatment diabetes and complication thereof.And infer that its hypoglycemic activity may be by Inhibiting α-glucosidase, stop intestinal tube to be realized sugared absorption.Simultaneously, utilize fluorimetry to measure the conjugate conformation of chimonin and insulin and glucagon, work out the increase along with chimonin content, the conjugate conformation of itself and insulin and glucagon changes, and this has just further proved that chimonin has the effect for the treatment of diabetes.5. pair myocardium protective effect.After injection chimonin; cardiac muscular tissue's tumor necrosis factor (TNF-a) and cardiac muscular tissue's myeloperoxidase (MPer) (MPO) obviously reduce; show that chimonin has protective effect to myocardial ischemia reperfusion injury (MI/R); and the infiltration that can alleviate cardiac muscular tissue's neutrophilic granulocyte, and can the inflammation-inhibiting factor discharge.The myocardial infarction mice therapeutic effect discovery that chimonin causes isoprenaline, chimonin has improved the myocardium situation of mice, has increased the phospholipid level in heart.When the biochemical modification of chimonin and antioxidant status are observed in to myocardial infarction Mice Body, find that chimonin has certain protective effect to the cardiac muscle of mice; In the Mice Body of injection ISPH; find that the generation of ATP and the amount of oxidation of succinic acid obviously reduce, by the injection of chimonin, this situation is improved; the heart integrity of mice is effectively protected, and has proved that chimonin can change cardiovascular energy metabolism.6. antitumaous effect.Chimonin has very large effect in the peroxidation of formation, ATP enzyme level and lipid that changes glycoprotein, in the Mice Body of suffering from pulmonary carcinoma, glycoprotein level, ATP enzyme level, level of lipid all compared with normal mice rise appreciably, after injection chimonin, these indexs all drop to normal level, demonstrate good antitumaous effect.In addition, also have other effects of curing the disease of bibliographical information chimonin, as " protective effect of chimonin to rat gastric ulcer " " Liaoning University of TCM's journal " 2008, 10 (6), " chimonin causes the protective effect of hepatic injury to ethanol " " Guangxi Medical University's journal " 2008, 25 (5), " Immunotherapeutic effects of mangiferin mediated by the inhibition of oxidative stress to activated lymphocytes, neutrophils and macrophages " " Toxicology " 2005, 215, " Mangiferin Inhibits Passive Cutaneous Anaphylaxis Reaction and Pruritus in Mice " " Planta Med " 2009, 13, " impact of inflammatory factor after chimonin commute apoplectic type spontaneous hypertensive rat cerebral ischemia re-pouring " " Chinese hypertension magazine " 2010, 18 (4).
Fructus Momordicae is as the genuine medicinal materials in Guangxi, and its total saponin extracts mogroside, is a kind of novel and healthy sweeting agent, and its sugariness is 250-400 times of sucrose, but heat is far below sucrose.Meanwhile, Fructus Momordicae also has stronger health care, and therefore first " being the kind list of food and medicine " listed in by health ministry, the State Administration of Traditional Chinese Medicines.In recent years pharmacologically active, the exploitation etc. of Fructus Momordicae are studied compared with horn of plenty.Show according to literature research, Fructus Momordicae has pharmacologically active very widely, comprises relieving cough and resolving phlegm, antiinflammatory, antibacterial, blood sugar lowering, the multiple effect such as anticancer; Mogroside also has the pharmacologically active of significant relieving cough and resolving phlegm, antibacterial, antiinflammatory." Chinese public health " 2003,19 (10) delivered in " hypoglycemic activity of Fructus Momordicae extract to diabetic mice " and once reported, the effect that mogroside is affected to blood glucose by zoopery is studied.Give normal mouse and diabetic mice respectively with 0.5,1.0, the continuous gavage 30d Fructus Momordicae extract of dosage (containing mogroside) of 3.0g/kg, found that, on normal mouse blood sugar without impact; In, low dose group has hypoglycemic activity to diabetic mice, while being 0.5g/kg, blood glucose is down to (11.84 ± 4.24) mmol/L by (15.45 ± 5.76) mmol/L, and when 1.0g/kg, blood glucose is down to (15.08 ± 4.64) mmol/L by (15.52+5.70) mmol/L; And high dose group (3.0g/kg) mouse blood sugar rises to (20.35 ± 4.36) mmol/L by (15.54 ± 5.77) mmol/L on the contrary.Show that Fructus Momordicae extract dosage has the effect that reduces diabetic mice fasting glucose while being 0.5～1.0g/kg, and blood sugar decreasing effect there is dose dependent.The mogroside that " bioactivity research of mogroside " of " Chinese herbal medicine " 1999,30 (12) publication is 98% by purity respectively by 80,160,320mg/kg dosage gavage mice, ammonia spraying is drawn and coughs mice and all have antitussive action; If purity 50% mogroside is pressed 4.0g/kg and 8.0g/kg dosage gavage, the mouse cough that strong aqua ammonia is brought out also can obviously reduce cough number of times.The purity and the dosage that confirm mogroside directly have influence on mice cough suppressing effect." the cough-suppressing phlegm-dispelling functions research of mogroside " that " Food Additives Used in China " 2006 (1) delivered is by the cough-suppressing phlegm-dispelling functions research experiment of mogroside, find that mogroside can also increase the phenol red excretion amount of trachea of mice, promote Rana nigromaculata esophagus ciliated cell campaign, obviously increase its expectoration amount, prove that mogroside has the characteristic of improving respiratory tract function." Chinese medicine research " 2008, " research of Mogrosides on Experimental Liver Injury in Mice protective effect " of 19 (3) publications is found in the experimental study of Mogrosides on Experimental Liver Injury in Mice protective effect, mogroside can reduce the activity of immunological liver injury in mice alanine aminopherase in serum (ALT) and aspartate amino transferase (AST), superoxide dismutase (SOD) activity in the murine liver tissue that can raise homogenate, reduce malonaldehyde (MDA) content, obviously alleviate hepatic tissue pathology intensity of variation, illustrate that mogroside is to chmice acute, immunologic liver injury has protective effect." food research and development " 2012, 33 (2) " interior antioxidation actions of Fructus Momordicae water extract and sweet glycosides thereof " delivered are in the interior antioxidation action research of Fructus Momordicae water extract and sweet glycosides thereof, drink 60d (interpolation in mice drinking water of Fructus Momordicae water extract and mogroside measures the intermediate value of its addition in food) to hyperlipidemia model mice with the mogroside solution of 2% Fructus Momordicae water extract aqueous solution and 0.08%, result shows, Fructus Momordicae water extract and mogroside all obviously improve the activity of hyperlipidemia model mice serum glutathion peroxidase (GSH-PX) and SOD, obviously reduce the content of serum MDA.Show that Fructus Momordicae water extract and mogroside have strong antioxidant action." foreign medical science. Chinese medicine fascicle " 2003,25 (3) once publications " cancer suppressing action of sugariness material in Fructus Momordicae " in the cancer suppressing action test of mogroside with 7,12-dimethylbiphenyl is feared (DMBA) for initiator, TPA (TPA) are carcinogenic promoting agent, and mouse skin is carried out to two-stage carcinogenicity testing.Found that momordica glycoside V has cancer suppressing action, this to delay carcinogenesis even stronger than stevioside." Chinese food journal " 2008,8 (1) once delivered " mangosteen juice and mogroside are on the lipometabolic impact of Mouse Blood " to after the continuous gavage 60d of hyperlipidemia RBC immune complex flower rate rate (I-CR) mouse model 0.08% mogroside solution, find that hyperlipemia in mice serum total cholesterol (TC), total triacylglycerol (TG) content reduce, and HDL-C (HDL-C) content obviously raises.Illustrate that mogroside has the function that regulates blood lipid metabolism." food research and development " 2010, 31 (2) also deliver " mangosteen juice and the experimental study of mogroside preventing decayed tooth " in mangosteen juice and mogroside preventing decayed tooth experimentation, respectively by mangosteen juice, mogroside, sucrose, fructose, glucose, xylitol adds in basic culture solution, making final sugared concentration is 20g/L, under aseptic technique, Streptococcus mutans bacterium liquid is inoculated in respectively in each culture fluid in the ratio of 2% (volume fraction), Streptococcus mutans bacterium liquid is inoculated in respectively in each culture fluid according to 10% ratio, Streptococcus mutans bacterium liquid is inoculated in to the mangosteen juice that contains 20g/L in 10% ratio, in the sucrose culture fluid of the mogroside of 20g/L and 20g/L, mix, after cultivating, find, Streptococcus mutans is all starkly lower than sucrose in the speed of growth and the adhesion that contain in mangosteen juice culture fluid, but it is higher to produce acidity, growth and breeding hardly in the culture fluid that contains mogroside.Result shows, mogroside is a kind of low cariogenicity sucrose succedaneum, can be used as health high sweetener and uses.
Sum up and can find out from the above-mentioned document retrieving, chimonin, mogroside all have good therapeutical effect to the some diseases of human body.Chimonin, mogroside both all there is cough-relieving, reduce phlegm, the effect such as antiinflammatory, and applicant seminar by animal experiment study find both in cough-relieving, reduce phlegm, anti-inflammatory agent efficacious prescriptions mask has synergism, under same dose, both share than alone wherein a kind of drug effect and are improved, take both as principal agent exploitation there is cough-relieving, reduce phlegm, the Chinese medicine preparation of antiinflammatory, there is not yet so far relevant report.
Summary of the invention
The inventor's research and result of the test show, chimonin extract (chimonin), Fructus Momordicae extract (mogroside) all have cough-relieving, reduce phlegm, the pharmacological action of antiinflammatory, and both share in cough-relieving, reduce phlegm, anti-inflammatory agent efficacious prescriptions mask has synergism.The inventor is take chimonin, mogroside as principal agent, and assistant is further made Chinese medicine preparation with suitable appropriate adjuvant, is applied to clinically, and result shows good function of moistening and cleaning throat.
The present invention has the Chinese medicine preparation of moistening and cleaning throat effect, and its active component is chimonin) and mogroside; According to the difference of dosage form, choose different molding adjuvants, its weight percentage is as follows:
Chimonin 0.01-99.97%,
Mogroside 0.01-99.97%,
Adjuvant 0.01-99.97%.
Moistening and cleaning throat Chinese medicine preparation of the present invention, production technology comprises mixes chimonin, mogroside, adjuvant, suppresses or be deployed into several processes such as product.
Moistening and cleaning throat Chinese medicine preparation of the present invention be a kind ofly there is cough-relieving, reduce phlegm, the oral Chinese medicine preparation of anti-inflammatory efficacy, concrete dosage form has oral solid formulation to comprise granule, tablet, capsule, powder, oral liquid comprises soft extract, mixture, syrup.Adjuvant is that the pharmaceutic adjuvant of various medical standard universals comprises filler, correctives, lubricant, antiseptic etc., and filler is starch, Icing Sugar, dextrin, carboxymethyl starch and other common medicinal supplementary material; Lubricant is Polyethylene Glycol, magnesium stearate, Pulvis Talci and the pharmaceutic adjuvant with lubrication, and antiseptic is as sodium benzoate, Nipagin ester series etc.; Correctives is sweeting agent because of mogroside itself, need not choose other sweeting agents again, can regulate and control the taste of preparation by adjusting the proportioning of other adjuvants.
Substantive distinguishing features of the present invention and significant progress are:
1. find by animal experiment study, chimonin and mogroside in cough-relieving, reduce phlegm, anti-inflammatory agent efficacious prescriptions mask has synergism, under same dose, both share than alone wherein a kind of drug effect and are improved.
2. first chimonin is combined to utilization with mogroside, develop a kind of Chinese medicine preparation with remarkable function of moistening and cleaning throat.
The specific embodiment
The following example is used for illustrating the present invention, is not any restriction to protection domain of the present invention.
Embodiment mono-
Get appropriate chimonin, mogroside, add appropriate starch, appropriate sugar, uses 70% alcohol dampening, granulation, subpackage, i.e. granule.
Embodiment bis-
Get appropriate chimonin, mogroside, add appropriate starch, appropriate sugar, uses 70% alcohol dampening, and granulation adds appropriate Pulvis Talci to mix afterwards and uses tablet machine tabletting, obtains tablet.
Embodiment tri-
Get appropriate chimonin, mogroside, add appropriate soluble starch, appropriate sorbitol, uses 70% alcohol dampening, and granulation adds appropriate Pulvis Talci to mix afterwards and uses tablet machine tabletting, obtains guttural tablets.
Embodiment tetra-
Get appropriate chimonin, mogroside, add appropriate starch, appropriate carboxymethyl cellulose, appropriate cyclodextrin, uses 70% alcohol dampening, and granulation is directly encapsulated, is capsule.
In order to verify moistening and cleaning throat effect of the present invention, with reference to the regulation under " health food check with assessment technique standard " (2003 editions) function of moistening and cleaning throat item, carry out cough-relieving, reduce phlegm, antiinflammatory action animal experiment, and toxicity test, method and result are as follows:
One. the pharmacological results
1. resolve phlegm effect test
Get 40 of mices, be divided at random normal saline group (blank group, A group), dextromethorphan hydrobromide group (positive drug group, B group), two glycosides throat moistening and cleaning tablet low dose group (C group), two glycosides throat moistening and cleaning tablet high dose group (D group), 10 every group.Before experiment, mice fasting one day, can't help water.Experiment starts, the equal ig of each group gives medicine or the normal saline of corresponding dosage, dosage is 0.2mL/10g body weight, every Mus ip2% phenol red solution 0.5mL after 30min after administration, after ip30min, put to death animal, blunt separation trachea, clip is the trachea down to trachea bifurcation from thyroid cartilage, and each trachea section is put into the 5%NaHCO that fills in advance 1.5mL
3in solution test tube, ultrasonic 3min, makes the phenol red release completely in trachea section; Collect NaHCO
3liquid, in the centrifugal 10min of centrifuge 3000RPM, gets supernatant, puts in microplate reader, measures OD value at 546nm place; Calculate phenol red content by regression equation (standard curve).The phenol red content of correction that is calculated as follows every mice, the results are shown in Table 1.
Proofread and correct phenol red content=phenol red content (μ g)/Mouse Weight (kg)
The drafting of standard phenol red curve: accurately take with analytical balance a certain amount of phenol red, with 5% NaHCO
3aqueous solution dissolves, and is mixed with 11.4 μ gmL
-1solution, then carries out doubling dilution in turn, obtains the solution of following series concentration: 5.7 μ gmL
-1, 2.85 μ gmL
-1, 1.14 μ gmL
-1, 0.57 μ gmL
-1, 0.285 μ gmL
-1, 0.114 μ gmL
-1, 0.057 μ gmL
-1, 0.0285 μ gmL
-1, by microplate reader mensuration OD value.Take phenol red content, (μ is g) as vertical coordinate (Y), and OD value is abscissa (X), show that regression equation is Y=2.9303X-0.1002, correlation coefficient r=0.9996.
The absorbance of the phenol red experiment of table 1 mice trachea excretion (
n=10)
T check through between group, compares * P < 0.05 with A group; * P < 0.01
2. antitussive action test
Get 40 of mices, be divided at random normal saline group (blank group, A group), dextromethorphan hydrobromide group (positive drug group, B group), two glycosides throat moistening and cleaning tablet low dose group (C group), two glycosides throat moistening and cleaning tablet high dose group (D group), 10 every group.The equal ig of each group gives medicine or the normal saline of corresponding dosage, every day 1 time, 3d continuously, administration volume is 0.2mL/10g body weight, last is placed in mice in 4L bell glass to drawing by ammonia the method for coughing after 1 medicine 1h, with strong aqua ammonia constant-pressure atomization 20s in ultrasound atomizer of 25-28%, after spraying finishes, takes out immediately mice, take mice shrink abdominal part and dehisce greatly or little dehisce with s cough as cough index, record the cough number of times in cough latent period and 2min.The results are shown in Table 2.
Table 2 ammonia cause cough mouse experiment (
n=10)
T check through between group, compares * P < 0.05 with A group; * P < 0.01
3. antiinflammatory action test
3.1 mice ear experiments
Get 40 of mices, be divided at random normal saline group (blank group, A group), dextromethorphan hydrobromide group (positive drug group, B group), two glycosides throat moistening and cleaning tablet low dose group (C group), two glycosides throat moistening and cleaning tablet high dose group (D group), 10 every group.Every Mus i.g0.2ml/10g every day weight, continuously 7d.After last administration 45min, auris dextra drips to be smeared dimethylbenzene 0.02ml and causes inflammation, after 15min, de-cervical vertebra is put to death mice, lay both sides auricle along left and right auricle same area with 6mm card punch, put on analytical balance and weigh respectively immediately, the difference of auris dextra sheet weight and left auricle weight is auricle swelling degree (mg).The results are shown in Table 3.
3.2 mouse peritoneal permeability experiments
Get 40 of mices, be divided at random normal saline group (blank group, A group), dextromethorphan hydrobromide group (positive drug group, B group), two glycosides throat moistening and cleaning tablet low dose group (C group), two glycosides throat moistening and cleaning tablet high dose group (D group), 10 every group.Every Mus i.g0.2ml/10g every day weight, continuously 7d.After last administration 45min, tail vein injection 0.25% Evans blue 0.1mL/10g body weight, i.p0.6% glacial acetic acid, 0.2mL/ is only.After 15min, de-cervical vertebra is put to death mice, cleans with 6mL normal saline lumbar injection, collects peritoneal fluid, in the centrifugal 10min of centrifuge 3000RPM, gets supernatant, puts in microplate reader, in the mensuration OD of 590nm place value.The results are shown in Table 4.
Table 3 mice auricle swelling degree (
n=10)
T check through between group, compares * P < 0.05 with A group; * P < 0.01
The absorbance of table 4 mouse peritoneal capillary permeability experiment (
n=10)
T check through between group, compares * P < 0.05 with A group; * P < 0.01
Two. toxicological experiment result
1. this product is to per os LD female, male mice
50all be greater than 10g/kg (be equivalent to human body recommended amounts 100 times), according to the acute toxicity grading evaluation criteria of food, the acute oral toxicity of this product belongs to nontoxic level.
2. take 90 days to rat with 75,150,300 times this product that is equivalent to people's consumption respectively, do not find rat growthing development to produce toxic action.
Claims (1)
1. a Chinese medicine preparation, is characterized in that: active component is chimonin and mogroside, and its weight percentage is: chimonin accounts for 0.01～99.97%, and mogroside accounts for 0.01～99.97%, and adjuvant accounts for 0.01～99.97%; Adjuvant, according to dosage form difference, is chosen from pharmaceutic adjuvant, adopts usual formulation method, makes buccal tablet, granule, tablet, capsule, mixture, syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410166661.1A CN103893194A (en) | 2014-04-24 | 2014-04-24 | Traditional Chinese medicine preparation and production method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410166661.1A CN103893194A (en) | 2014-04-24 | 2014-04-24 | Traditional Chinese medicine preparation and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893194A true CN103893194A (en) | 2014-07-02 |
Family
ID=50984982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410166661.1A Pending CN103893194A (en) | 2014-04-24 | 2014-04-24 | Traditional Chinese medicine preparation and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893194A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021134394A1 (en) * | 2019-12-31 | 2021-07-08 | L'oreal | Composition comprising phenolic compounds and hydrotropes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810591A (en) * | 2010-03-31 | 2010-08-25 | 昆明制药集团股份有限公司 | Mangiferin dispersible tablets and preparation method thereof |
| CN103212014A (en) * | 2013-03-14 | 2013-07-24 | 慈明塔 | Chinese medicinal composition for treating chronic pharyngitis |
-
2014
- 2014-04-24 CN CN201410166661.1A patent/CN103893194A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810591A (en) * | 2010-03-31 | 2010-08-25 | 昆明制药集团股份有限公司 | Mangiferin dispersible tablets and preparation method thereof |
| CN103212014A (en) * | 2013-03-14 | 2013-07-24 | 慈明塔 | Chinese medicinal composition for treating chronic pharyngitis |
Non-Patent Citations (1)
| Title |
|---|
| 陈瑶等: "罗汉果甜苷的止咳祛痰作用研究", 《中国食品添加剂》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021134394A1 (en) * | 2019-12-31 | 2021-07-08 | L'oreal | Composition comprising phenolic compounds and hydrotropes |
| CN115297832A (en) * | 2019-12-31 | 2022-11-04 | 莱雅公司 | Compositions comprising phenolic compounds and hydrotropes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luan et al. | Recent advances in Camellia oleifera Abel: A review of nutritional constituents, biofunctional properties, and potential industrial applications | |
| Mitra et al. | Prospective multifunctional roles and pharmacological potential of dietary flavonoid narirutin | |
| Jalwal et al. | Recent advances on senna as a laxative: a comprehensive review | |
| Thakur et al. | Rasayana properties of Ayurvedic herbs: Are polysaccharides a major contributor | |
| Modaresi et al. | The effect of Taraxacum officinale hydroalcoholic extract on blood cells in mice | |
| KR100697056B1 (en) | Composition comprising liquiritigenin for preventing and treating liver disease | |
| KR20100138576A (en) | A composition for the prevention and treatment of inflammatory disease comprising the mixture of extract of notopterygium incisum and saposhnikovia divaricata as an effective ingredient | |
| CN102920696A (en) | Application of mangiferin compound or mango extraction as pancreatic lipase inhibitor and to preparation of medicament or food for preventing and treating obesity | |
| CN101474375B (en) | Compound Cordyceps militaris L. Link preparation and production method and application | |
| CN101301401A (en) | Camellia effective ingredients and extracting method and use thereof | |
| Bucar et al. | Flavonoid C-glycosides in diets | |
| KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
| CN105582003A (en) | Application of methyl ferulic acid in preparation of medicine for preventing and treating alcoholic liver disease | |
| CN1733125B (en) | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark | |
| CN103893194A (en) | Traditional Chinese medicine preparation and production method thereof | |
| CN101948453B (en) | Novel NEO-clerodane typed diterpene compound and application thereof | |
| CN103463217B (en) | A kind of treat enteritis and dysentery extract, containing its preparation and its preparation method and application | |
| CN110731509A (en) | A health product containing prebiotics for lowering blood sugar and blood lipid, and its preparation method | |
| CN103880913B (en) | A kind of compound and application thereof with hepatoprotective effect | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN100562325C (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| Gou et al. | Traditional uses, phytochemistry, and pharmacology of Persicaria orientalis (L.) Spach-A review | |
| CN103923156B (en) | There is saponin compound and the application thereof of hepatoprotective effect | |
| Matera et al. | Sedative and antispasmodic effects of Stevia rebaudiana and noncompetitive inhibition of intestinal contractility by stevioside | |
| CN103864883B (en) | There is the triterpene saponin compound of liver protection function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140702 |